Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenpep (EUR-1008) in Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT00297167Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- May 2006
- Primary completion
- Nov 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pancreatin in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Forest Laboratories. Primary endpoint: Coefficient of Fat Absorption. Started May 2006; status: completed.
02
Drugs
pancreatin
03
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00297167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297167.